California SB1023 mandates coverage of FDA-approved antiretroviral drugs, devices, and products for HIV/AIDS prevention in health care plans and.

California SB1023 requires health care service plans and health insurers to cover FDA-approved antiretroviral drugs, devices, and products for HIV/AIDS prevention, including preexposure and postexposure prophylaxis. It prohibits these entities from imposing prior authorization or step therapy on these medications. The bill also mandates coverage of pharmacist-provided prophylaxis services and related testing. The provisions apply to plans and policies issued, amended, or renewed after January 1, 2027, excluding specialized plans and Medi-Cal managed care plans.

California SB1023 mandates coverage of FDA-approved antiretroviral drugs, devices, and products for HIV/AIDS prevention in health care plans and.

California SB1023 requires health care service plans and health insurers to cover FDA-approved antiretroviral drugs, devices, and products for HIV/AIDS prevention, including preexposure and postexposure prophylaxis. It prohibits these entities from imposing prior authorization or step therapy on these medications. The bill also mandates coverage of pharmacist-provided prophylaxis services and related testing. The provisions apply to plans and policies issued, amended, or renewed after January 1, 2027, excluding specialized plans and Medi-Cal managed care plans.